1. Home
  2. RAVE vs BTAI Comparison

RAVE vs BTAI Comparison

Compare RAVE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

HOLD

Current Price

$2.97

Market Cap

45.8M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

38.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
BTAI
Founded
1958
2017
Country
United States
United States
Employees
N/A
37
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.8M
38.5M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
RAVE
BTAI
Price
$2.97
$1.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$26.67
AVG Volume (30 Days)
25.6K
310.9K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.09
N/A
Revenue
$15,120,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
$33.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$1.17
52 Week High
$3.75
$8.08

Technical Indicators

Market Signals
Indicator
RAVE
BTAI
Relative Strength Index (RSI) 38.54 48.75
Support Level $2.73 $1.50
Resistance Level $3.21 $1.72
Average True Range (ATR) 0.17 0.11
MACD -0.04 0.02
Stochastic Oscillator 11.27 53.12

Price Performance

Historical Comparison
RAVE
BTAI

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: